Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

More than insulin

For a century, insulin has been the only drug available to type 1 diabetics. Now a raft of novel drugs are coming through the pipeline. Michael Eisenstein reports.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Growing a new pancreas.

Source: ViaCyte


  1. Fischer, B. et al. Expert Opin. Biol. Ther. 2, 265–272 (2010).

    Article  Google Scholar 

  2. Couri, C.E. et al. J. Am. Med. Assoc. 301, 1573–1579 (2009).

    Article  CAS  Google Scholar 

  3. Tang, Q. et al. J. Exp. Med. 199, 1455–1465 (2004).

    Article  CAS  Google Scholar 

  4. Suarez-Pinzon, W.L. et al. Cell Transplant. 17, 631–640 (2008).

    Article  Google Scholar 

  5. Thorel, F. et al. Nature 464, 1149–1154 (2010).

    Article  CAS  Google Scholar 

  6. Skyler, J.S. et al. Diabetes Care 28, 1068–1076 (2005).

    Article  CAS  Google Scholar 

  7. Malecki, M. & Klusacek, M. Biosimilars: ESAs, Insulins, and Human Growth Hormones (Decision Resources, 2009). <>

    Google Scholar 

  8. El-Khatib, F.H. et al. Sci. Transl. Med. 2, 27ra27 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eisenstein, M. More than insulin. Nat Biotechnol 29, 782–785 (2011).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research